Tag: GLMD

Finance

Biotech Bullish Stocks: Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), Reliv International, Inc (NASDAQ:RELV), Recro Pharma Inc (NASDAQ:REPH), Ignyta Inc (NASDAQ:RXDX)

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) has seen a massive down tick in the past few trading sessions, and analysts believe that this downward trajectory might continue for the stock and may lead it to lower levels. Short term traders can short the stock at current levels with a tight stop loss at $11 for targets of $8 or lower. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) stock performance was … Continue reading Biotech Bullish Stocks: Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), Reliv International, Inc (NASDAQ:RELV), Recro Pharma Inc (NASDAQ:REPH), Ignyta Inc (NASDAQ:RXDX)

Colin Pettis
Finance

Biotech New Lows: Galmed Pharmaceuticals (NASDAQ:GLMD), Recro Pharma (NASDAQ:REPH), BioTime (NYSEMKT:BTX), Onconova Therapeutics (NASDAQ:ONTX)

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced the closing of its initial public offering of 3,263,010 ordinary shares at a public offering price of $13.50 per share, which included 425,610 ordinary shares issued upon the exercise in full of the underwriters’ option to purchase additional ordinary shares to cover over-allotments. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) stock performance was -1.58% in last session and finished the day at $10.93. … Continue reading Biotech New Lows: Galmed Pharmaceuticals (NASDAQ:GLMD), Recro Pharma (NASDAQ:REPH), BioTime (NYSEMKT:BTX), Onconova Therapeutics (NASDAQ:ONTX)

Jayne Crisman
Finance

Biotech New Lows: Akebia Therapeutics (NASDAQ:AKBA), Galmed Pharmaceuticals (NASDAQ:GLMD), Tetralogic Pharmaceuticals (NASDAQ:TLOG), Dipexium Pharmaceuticals (NASDAQ:DPRX)

Akebia Therapeutics Inc. (NASDAQ:AKBA) offered 5.9 million shares in its Thursday IPO at $17 a share, the high end of the stock’s expected price range. Among other therapeutics, the biopharma company is developing a once-daily oral therapy for patients with kidney disease. Akebia Therapeutics, Inc. (NASDAQ:AKBA) stock performance was -0.99% in last session and finished the day at $20.00. Traded volume was 219,904 million shares … Continue reading Biotech New Lows: Akebia Therapeutics (NASDAQ:AKBA), Galmed Pharmaceuticals (NASDAQ:GLMD), Tetralogic Pharmaceuticals (NASDAQ:TLOG), Dipexium Pharmaceuticals (NASDAQ:DPRX)

Kevin Long
Finance

Biotech New Lows: VIVUS (NASDAQ:VVUS), Dipexium Pharmaceuticals (NASDAQ:DPRX), Tetralogic Pharmaceuticals (NASDAQ:TLOG), Galmed Pharmaceuticals (NASDAQ:GLMD)

VIVUS, Inc. (NASDAQ:VVUS) announced that Shari Belafonte is teaming up with the company to educate American adults about seeking medical treatment for chronic weight management when diet and physical activity alone have not been successful. Ms. Belafonte, an actress, model, photographer, writer, singer and daughter of famed musician and actor Harry Belafonte, knows that the impact of being overweight is more than superficial. VIVUS, Inc. … Continue reading Biotech New Lows: VIVUS (NASDAQ:VVUS), Dipexium Pharmaceuticals (NASDAQ:DPRX), Tetralogic Pharmaceuticals (NASDAQ:TLOG), Galmed Pharmaceuticals (NASDAQ:GLMD)

Chris Lewis
FB Nasdaq FB Facebook
Finance

Biotech Losers: Agenus Inc (NASDAQ:AGEN), La Jolla Pharmaceutical Company (NASDAQ:LJPC), Durata Therapeutics (NASDAQ:DRTX), Galmed Pharmaceuticals (NASDAQ:GLMD)

Shares of Agenus Inc (NASDAQ:AGEN) , a biopharmaceutical company focused on developing novel immunotherapies to treat cancer and a number of other unmet diseases, tumbled by as much as 22% after partner GlaxoSmithKline (NYSE: GSK ) announced that its phase 3 MAGE-A3 cancer immunotherapeutic trial in non-small cell lung cancer (NSCLC) patients didn’t meet its first or second coprimary endpoint. Agenus Inc (NASDAQ:AGEN) stock performance … Continue reading Biotech Losers: Agenus Inc (NASDAQ:AGEN), La Jolla Pharmaceutical Company (NASDAQ:LJPC), Durata Therapeutics (NASDAQ:DRTX), Galmed Pharmaceuticals (NASDAQ:GLMD)

Kevin Long